Zura Bio Updates Corporate Outlook on Lead Tibulizumab Program

The latest announcement is out from Zura Bio ( (ZURA) ).

On March 10, 2026, Zura Bio Ltd., a clinical-stage biotechnology company developing therapies for complex immune disorders, released an updated corporate presentation highlighting its lead asset tibulizumab, a first-in-class bispecific antibody inhibiting both IL-17 and BAFF. The drug, engineered from components of tabalumab and ixekizumab, has shown potent target engagement and low immunogenicity in completed Phase 1 studies, and is being advanced initially in hidradenitis suppurativa and systemic sclerosis, where management sees potential for best-in-class efficacy and first-in-disease treatment across skin and lung manifestations.

The presentation underscores Zura Bio’s strengthened financial position, noting $109 million in cash at year-end 2025 and $144 million in gross proceeds from a February 26, 2026 public offering, which together are expected to fund operations through at least the end of 2028. Topline Phase 2 data readouts for hidradenitis suppurativa and systemic sclerosis are planned for the fourth quarter of 2026 and the first half of 2027, respectively, setting key near-term value inflection points for shareholders as the company seeks to solidify its position in the competitive autoimmune therapeutics space, with about 124 million shares outstanding on an as-converted basis as of March 3, 2026.

The most recent analyst rating on (ZURA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.

Spark’s Take on ZURA Stock

According to Spark, TipRanks’ AI Analyst, ZURA is a Neutral.

Score is held back primarily by weak financial performance (pre-revenue, widening losses, and significant cash burn), partially offset by strong technical momentum and positive corporate updates supporting clinical progress and a stated funding runway through 2027. Valuation signals remain constrained by unprofitability and lack of dividend data.

To see Spark’s full report on ZURA stock, click here.

More about Zura Bio

Zura Bio Ltd. is a clinical-stage biotechnology company focused on developing differentiated therapies for complex immune and autoimmune disorders. Its lead program, tibulizumab, is a first-in-class bispecific antibody targeting both the IL-17 and BAFF pathways, with an initial clinical focus on hidradenitis suppurativa and systemic sclerosis, where dual-pathway inhibition aims to address disease mechanisms involving both B- and T-cell activation.

The company reports robust financing to support its pipeline, with $109 million in cash as of Dec. 31, 2025, and $144 million in gross proceeds from a public offering that closed on Feb. 26, 2026. Following this raise, Zura Bio expects to fund planned operations through at least the end of 2028, and has approximately 124 million shares outstanding on an as-converted basis as of March 3, 2026, excluding potential dilution from options and unvested RSUs.

Average Trading Volume: 689,673

Technical Sentiment Signal: Buy

Current Market Cap: $607M

See more data about ZURA stock on TipRanks’ Stock Analysis page.